BPI-002 / BeyondSpring - LARVOL DELTA

BeyondSpring files for patent protection on BPI-002 for the treatment of viral infections including Covid-19 (GlobeNewswire) - "BeyondSpring...today announced the submission of a provisional U.S. patent application for its pipeline asset BPI-002...when administered alone or in combination with a vaccine....BPI-002 can potentially activate the adaptive immune system...to directly attack and kill virally infected cells, including RNA virus....If combined with a vaccine, including COVID-19 vaccine, BPI-002 can potentially function as an adjuvant to provide improved long-term humoral (B-cell dependent) protection against future viral infection."

Patent